Celsion Corp. (CLSN)

3.17
0.10 3.10
NASDAQ : Health Technology
Prev Close 3.27
Open 3.30
Day Low/High 3.10 / 3.31
52 Wk Low/High 1.24 / 6.06
Volume 366.83K
Avg Volume 232.60K
Exchange NASDAQ
Shares Outstanding 17.73M
Market Cap 54.44M
EPS -2.70
P/E Ratio 25.58
Div & Yield N.A. (N.A)

Latest News

Celsion Corporation To Present At Upcoming Investor Conferences

Celsion Corporation To Present At Upcoming Investor Conferences

Company to Discuss its Ongoing Pivotal Phase III and its Phase II Clinical Studies in Oncology

Celsion Announces Ovarian Cancer Expert Presentation At Oppenheimer & Co. Investor Event

Celsion Announces Ovarian Cancer Expert Presentation At Oppenheimer & Co. Investor Event

Discussion Included Overview of Ovarian Cancer Treatment Landscape and Celsion's Immunotherapy Product Candidate, GEN-1 Presentation Available on Celsion's Website

Celsion Announces ThermoDox® HEAT Study Presentation At Korean Liver Cancer Association's 12th Annual Scientific Meeting

Celsion Announces ThermoDox® HEAT Study Presentation At Korean Liver Cancer Association's 12th Annual Scientific Meeting

-Thesis Supporting the Phase III OPTIMA Study Chosen for the Presidential Selection Lecture by the Academic Committee - - Celsion to Host Symposium on Hepatocellular Carcinoma at International Liver Congress 2018 in April -

Celsion Provides Summary Of Research And Development Day Held On October 12, 2017

Celsion Provides Summary Of Research And Development Day Held On October 12, 2017

Leading Ovarian Cancer and Immunotherapy Experts Discuss GEN-1 Clinical Programs in Newly Diagnosed Stage III/IV Ovarian Cancer Patients

Celsion Provides Summary Of Research And Development Day Held On Thursday, October 12, 2017

Celsion Provides Summary Of Research And Development Day Held On Thursday, October 12, 2017

Leading Liver Cancer Experts Discuss ThermoDox® Clinical Programs in Primary Liver Cancer

Celsion To Host Research And Development (R&D) Day On Thursday, October 12, 2017

Celsion To Host Research And Development (R&D) Day On Thursday, October 12, 2017

Leading Experts to Discuss Clinical Programs in Primary Liver Cancer and Ovarian Cancer

Celsion To Host Research And Development Update October 12, 2017

Celsion To Host Research And Development Update October 12, 2017

Leading Experts to Discuss Clinical Programs in Primary Liver Cancer and Ovarian Cancer

Celsion Announces Presentation Of OVATION Study Findings At The Upcoming AACR Special Conference

Celsion Announces Presentation Of OVATION Study Findings At The Upcoming AACR Special Conference

Company to Report Final Clinical and Translational Research Data

Celsion Corporation Reports Second Quarter 2017 Financial Results And Provides Business Update

Celsion Corporation Reports Second Quarter 2017 Financial Results And Provides Business Update

Company to Hold Conference Call on Tuesday, August 15, 2017 at 11:00 a.m. ET

Celsion Announces Latest Translational Data From The OVATION Study In Newly Diagnosed Advanced Ovarian Cancer Patients

Celsion Announces Latest Translational Data From The OVATION Study In Newly Diagnosed Advanced Ovarian Cancer Patients

Patients in All Cohorts Show Convincing Evidence of IL-12 Gene Transfer and Immune System Activity

This Biotech Stock Is Surging More Than 20% Today

This Biotech Stock Is Surging More Than 20% Today

Here are the names.

TheStreet Quant Rating: D- (Sell)